Chief Executive Officer
Roger Moody is Biocartis' Chief Executive Officer since 24 April 2023. Mr. Moody has more than 30 years of experience in the technology and healthcare industries with a focus on scaling up molecular diagnostics companies. He has held senior executive positions leading companies through manufacturing and commercial scale-up while securing funding in both private and public offerings. Prior to joining Biocartis, Mr. Moody served as CEO of GlySure Limited, whose primary assets were sold to Baxter International (NYSE: BAX), and held the CFO position at Nanosphere (now part of DiaSorin (Euronext Milan: DIA)), Clinical Genomics, Inc., a liquid biopsy company) and most recently Talis Biomedical (Nasdaq: TLIS), a point-of-care molecular diagnostics company. Mr. Moody started his career at IBM where he served in various roles supporting the formation and rapid growth of IBM Global Services. Roger Moody holds a BS in Finance from Syracuse University and an MBA from The University of Chicago Booth School of Business.
